HANGZHOU, China, May 30, 2026 – BlissBio announces today that a poster will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
HANGZHOU, China, May 30, 2026 – BlissBio announces today that a poster will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, showing preliminary results from a Phase II study evaluating the safety and efficacy of BB-1701 in combination with sintilimab in patients with locally advanced or metastatic HER2 low-expressing breast cancer or HER2-mutated non-small cell lung cancer (NSCLC). The ASCO Annual Meeting will take place from May 29 to June 2, 2026, in Chicago, USA.
Title: A phase II study to evaluate the safety and efficacy of BB-1701 in combination with sintilimab in patients with HER2 expression or mutation in locally advanced/metastatic breast cancer or NSCLC. Abstract #: 2632 Poster Bd #: 422 Session Title: Developmental Therapeutics—Immunotherapy Session Time: 1:30 PM-4:30 PM on May 30, 2026 CDT |
Media Inquiries
Bliss Biopharmaceutical Co., Ltd.
TEL: +86-0571-86808367
E-mail: office@blissbiopharma.com
